Tuberculosis (TB) is among the oldest infectious diseases, with historical evidence found in the skeletal remains and mummies of ancient civilizations such as Egypt, Greece, and Rome. During the Middle Ages and the Renaissance, TB earned the titles "White Plague" and "Captain of All These Men of Death" due to its widespread devastation. [1] The Industrial Revolution exacerbated TB outbreaks by fostering overcrowded urban environments with poor sanitation, malnutrition, and inadequate housing. [2] [3] These conditions led to the establishment of sanatoriums where patients were treated through isolation, rest, and nutrition-focused therapy. [4] [5] Robert Koch’s discovery of Mycobacterium tuberculosis in 1882 revolutionized the diagnosis and treatment of TB, marking a pivotal moment in the understanding of its pathogenesis. [6] However, despite scientific advancements, TB remains one of the most lethal infectious diseases globally. This review aims to explore the evolution of TB, its epidemiology, and the challenges posed by drug-resistant strains, focusing on Pakistan, a high-burden country.

Drug-Resistant Tuberculosis

The emergence of drug-resistant strains, such as multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), has become a significant global health threat. MDR-TB shows resistance to at least two first-line drugs (isoniazid and rifampicin), while XDR-TB exhibits resistance to fluoroquinolones and at least one second-line injectable drug. [7] These strains primarily arise from inappropriate treatment regimens, poor patient compliance, and transmission in healthcare settings. Pakistan faces particular challenges in controlling MDR-TB and XDR-TB due to factors such as malnutrition, overcrowding, limited healthcare infrastructure, and the burden of HIV/AIDS. [8] [9]

Epidemiology of TB and Drug-Resistant Strains in Pakistan

In 2020, approximately 525,000 new TB cases were reported in Pakistan, ranking it among the countries with the highest TB burdens. [10] Drug-resistant TB has become particularly prevalent in urban centers due to inadequate infection control measures, misuse of antibiotics, and delayed diagnoses. [11] The socioeconomic impact of TB includes lost productivity, increased healthcare costs, and stigma, further complicating disease management. [9]

Mechanisms and Transmission of Mycobacterium tuberculosis

TB is caused by Mycobacterium tuberculosis, a rod-shaped, acid-fast bacterium transmitted through aerosolized droplets released by infected individuals during activities like coughing or sneezing. [12] [13] The bacterium's complex cell wall, containing mycolic acids and lipoarabinomannan, enables it to resist antibiotics and evade host immune responses. [14] Upon entering the lungs, TB bacteria are engulfed by macrophages but can survive and multiply within these cells. The infection may remain latent or progress to active disease depending on the host's immune response. [3]

Global TB control strategies have evolved significantly, with the introduction of Directly Observed Treatment, Short-Course (DOTS), and programs aimed at ensuring universal access to TB medications. [15] However, MDR-TB and XDR-TB present considerable challenges, particularly in countries like Pakistan, where healthcare systems struggle with resource limitations and inadequate infrastructure. [16] Collaborative efforts between national and international organizations are essential to develop innovative diagnostic methods and treatment regimens to combat drug-resistant TB effectively.

Clinical Manifestations:

Tuberculosis (TB), caused by Mycobacterium tuberculosis, presents through multiple clinical stages, with manifestations varying based on the host's immune response. These stages include latency, primary disease, primary progressive disease, and extrapulmonary involvement. Understanding these stages and their pathogenesis is crucial for timely diagnosis and intervention to prevent complications such as dissemination and systemic involvement.

Latency

Latent tuberculosis infection (LTBI) occurs when individuals harbor M. tuberculosis without showing clinical symptoms. Though the bacteria remain dormant, they can reactivate under certain immunocompromising conditions, leading to active TB. Bacteria are engulfed by alveolar macrophages upon inhalation. M. tuberculosis survives intracellularly by inhibiting phagosome-lysosome fusion, enabling replication and immune evasion. The immune response leads to granuloma formation, which contains the infection. Infected individuals are asymptomatic and non-contagious, but factors such as HIV, diabetes, aging, or immunosuppression can trigger reactivation. [17] Reactivation may progress to active TB, increasing the risk of systemic involvement. [18]

Primary Disease

Primary tuberculosis occurs soon after the initial infection with M. tuberculosis and primarily affects the lungs, though other organs may also be involved. Infection begins when inhaled bacteria reach the alveoli, where they are phagocytosed by macrophages. The bacteria replicate and activate the immune system, leading to granuloma formation. Common symptoms include fever, night sweats, fatigue, weight loss, cough, and chest pain. Hemoptysis (coughing up blood) may occur in pulmonary TB cases. [19] Spread via lymphatic pathways may cause parabrachial lymphadenopathy and pleural effusion, leading to dyspnea and pleuritic chest pain. [20]

Fig. 1: Mechanism of pathogenesis for Primary Tuberculosis: Transmission of Mycobacterium tuberculosis, Inhalation of Mycobacterium tuberculosis by airborne droplets leading to active TB disease, Potential dissemination through bloodstream.

Primary Progressive Disease

Primary progressive tuberculosis occurs when the immune system fails to control the initial infection, resulting in a worsening disease state. The bacteria survive by inhibiting phagosome-lysosome fusion, replicating intracellularly, and killing macrophages. Granulomas may fail to contain the infection, leading to lung tissue damage and cavity formation. [21] Persistent cough, sputum production, chest pain, and dyspnea are common. Advanced cases may show systemic symptoms like weight loss, finger clubbing, and night sweats. [22] Without treatment, disease progression may lead to disseminated TB or military TB, with small lesions across multiple organs. [23].

Fig. 2: Mechanism of pathogenesis for Primary Progressive Tuberculosis (PPTB): Intracellular replication of bacteria, Macrophage Death and then Bacterial Release. Recruitment of immune cells leading to granuloma formation. Immune Response Activation and recruitment of immune cells (macrophages, T cells) form granulomas which contain the infection. Failure of these granulomas to contain bacteria (Primary Progressive TB).

Extra-pulmonary Tuberculosis (EPTB)

Extra-pulmonary tuberculosis (EPTB) occurs when M. tuberculosis spreads beyond the lungs, affecting various organs such as lymph nodes, bones, joints, and the central nervous system. Dissemination occurs through the bloodstream or lymphatic system. Granulomas may form in extra-pulmonary sites, such as bones (osteomyelitis), pleura (pleuritis), or meninges (meningitis). [24] Symptoms vary by site, including neurological deficits in CNS involvement or joint pain in skeletal TB. General symptoms include fever, weight loss, and malaise. Immunocompromised patients are more vulnerable to severe forms of EPTB, such as tuberculous meningitis or military TB. [25]

Fig. 3: Mechanism of pathogenesis for Extra-Pulmonary Tuberculosis (EPTB): Outlines the critical steps in the pathogenesis of Extra-pulmonary Tuberculosis, emphasizing the progression from initial infection in the lungs to the spread and colonization of other organs, leading to a range of symptoms depending on the affected site

Active tuberculosis (TB) is often suspected based on abnormal findings in chest radiographs, which typically reveal infiltrates and cavitation in the upper and middle lung lobes. However, atypical presentations may occur, particularly in elderly patients or those with advanced HIV infection. [26] While chest radiographic abnormalities can indicate TB, they are not definitive for diagnosis. The initial laboratory test for TB diagnosis involves the examination of sputum smears for acid-fast bacilli, which suggests potential infectiousness. Traditionally, three sputum specimens are collected over consecutive days; however, recent studies indicate that two specimens may yield similar sensitivity. This test provides a rapid, albeit nonspecific, assessment to determine the need for respiratory precautions pending confirmatory results. [17] Definitive diagnosis requires the identification of Mycobacterium tuberculosis in culture, primarily from sputum samples, with growth on solid media taking 3 to 6 weeks. Newer techniques, such as high-performance liquid chromatography, can confirm the presence of TB within 4 to 14 days. [28] Monitoring culture conversion, where cultures become negative after initially testing positive, serves as a crucial measure of treatment efficacy. [29] For patients from whom sputum is difficult to obtain, bronchoscopy with bronchial washings or bronchoalveolar lavage can be utilized. Emerging diagnostic methods, including nucleic acid amplification tests like polymerase chain reaction (PCR) assays, offer rapid confirmation but are limited by sensitivity and specificity. Interferon-gamma release assays, such as Quantiferone-TB Gold, have supplanted tuberculin skin tests for detecting latent TB due to their superior sensitivity and specificity. [20]

Timely and accurate diagnosis of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB is vital for initiating appropriate treatment and preventing further transmission. [30] Traditional sputum smear microscopy and culture-based methods exhibit limitations in detecting drug resistance, necessitating the incorporation of molecular assays and phenotypic drug susceptibility testing. Innovations in rapid molecular diagnostics, such as Xpert MTB/RIF and line probe assays, have transformed TB diagnosis by enabling simultaneous detection of TB and rifampicin resistance within hours. [31]

Biochemical Assays

Numerous serum biomarkers correlate with TB infection and disease severity, including acute-phase proteins like C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), which are elevated during inflammation and can assist in evaluating tissue damage and systemic inflammation in TB patients. [32]

Liver function tests (LFTs) are essential for monitoring potential hepatotoxicity caused by first-line TB medications such as isoniazid and rifampicin. Routine assessments of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin levels are conducted to detect drug-induced liver injury and guide treatment modifications. Similarly, renal function tests are critical, as certain TB drugs can induce nephrotoxicity; therefore, serum creatinine and blood urea nitrogen (BUN) levels are routinely evaluated. [22]

Electrolyte imbalances, particularly in advanced TB or co-morbid conditions like HIV/AIDS, necessitate regular monitoring of serum electrolyte levels, including sodium, potassium, and magnesium. [33] Blood glucose levels require vigilant monitoring in TB patients with diabetes mellitus, as poor glycemic control is associated with adverse outcomes. Dyslipidemia is also prevalent in TB patients, linked to chronic inflammation and malnutrition, thus necessitating lipid profile analysis to evaluate cardiovascular risk. [34] Nutritional assessments, including serum albumin, prealbumin, and total protein levels, are vital for identifying malnourished patients and implementing appropriate interventions.

Immunodiagnostic Tests

Two widely used immunodiagnostic tests for TB include the tuberculin skin test (TST) and interferon-gamma release assays (IGRAs), particularly when conventional methods like sputum smear microscopy or culture lack sensitivity:

Tuberculin Skin Test (TST): The TST involves injecting a purified protein derivative (PPD) into the forearm, with the induration measured 48 to 72 hours later. [35] This test measures delayed-type hypersensitivity to TB antigens but cannot differentiate between latent TB infection (LTBI) and active TB disease, and may yield false-positive or false-negative results under certain conditions. [36]

Interferon-Gamma Release Assays (IGRAs): IGRAs assess the release of interferon-gamma (IFN-γ) from T cells in response to specific TB antigens. Commercially available assays include Quantiferone-TB Gold In-Tube and T-SPOT.TB. IGRAs demonstrate higher specificity than TST, especially in BCG-vaccinated individuals, though they are more expensive and require laboratory facilities. [37]

Serological Tests:

Enzyme-linked immunosorbent assays (ELISA) and rapid immunochromatographic tests detect antibodies against TB antigens; however, their sensitivity and specificity are limited, especially in HIV-infected individuals, leading to their non-recommendation by the World Health Organization (WHO). [38]

Phenotypic Characterization

Culture methods involve processing sputum samples in a biosafety cabinet to minimize exposure risk. Following decontamination, sputum samples are inoculated onto solid culture media, such as Lowenstein-Jensen (LJ) or Middlebrooks agar, and incubated at 37°C for four to six weeks. [39] The growth of characteristic MTB colonies is monitored, and once visible, they are subculture onto fresh media for further testing and identification.

Molecular methods, such as polymerase chain reaction (PCR), are employed to confirm the presence of MTB and assess drug susceptibility. Drug resistance primarily arises from spontaneous mutations in genes responsible for drug targets or metabolic pathways. [22] Various biochemical tests, including the Nitrate Reductase Test, Peroxidase Test, Tween 80 Hydrolysis Test, Niacin Test, and Pyrazinamidase Test, further aid in the identification of MTB and its characteristics.

Genotypic Characterization

Genetic factors significantly influence susceptibility to tuberculosis, with specific mutations in genes implicated in mycobacterial infections. Molecular techniques such as PCR, including real-time PCR (qPCR), enable the amplification of specific MTB genomic regions, enhancing detection sensitivity. The GeneXpert MTB/RIF assay, a cartridge-based nucleic acid amplification test, allows simultaneous detection of TB and rifampicin resistance mutations. [22]

Table 1: Target genes with mechanism of action to drug resistance.

TREATMENT AND MANAGEMENT OF TUBERCULOSIS

The treatment and management of tuberculosis (TB) involve a multifaceted approach, incorporating antimicrobial therapy, patient education, and public health interventions (Brosch et al., 1999). The following sections outline the critical aspects of TB treatment and management.

ANTIMICROBIAL THERAPY

Table 2: List of Drugs involve in First line & Second line

Treatment Regimens: TB treatment typically consists of an initial intensive phase followed by a continuation phase. Treatment duration and specific drug regimens depend on the patient’s age, drug susceptibility test results, and the presence of drug-resistant TB. [33]

Directly Observed Therapy (DOT): The World Health Organization (WHO) recommends DOT to enhance treatment adherence and completion. In this approach, healthcare providers directly observe patients taking their medications, which helps prevent treatment failure and the emergence of drug resistance. [40]

PATIENT EDUCATION

Counseling: Educating TB patients about the importance of adherence to their treatment regimen is essential for ensuring cure and preventing drug resistance. Side Effects Monitoring: Patients should be informed about potential side effects of TB medications and encouraged to report any adverse reactions promptly. Infection Control Measures: Educating patients about infection control measures, such as covering their mouth when coughing and practicing good respiratory hygiene, is crucial to prevent TB transmission. [41]

PUBLIC HEALTH INTERVENTIONS

Contact Tracing: Public health authorities conduct contact tracing to identify and screen individuals who may have been exposed to TB patients, facilitating early detection and treatment of latent TB infection or active disease. Screening and Testing: Targeted screening programs are essential for identifying individuals at risk for TB infection or disease, especially high-risk populations such as healthcare workers, prisoners, and individuals living with HIV/AIDS. [42]

PREVENTION AND CONTROL STRATEGIES

Effective prevention and control strategies for tuberculosis (TB) are crucial for reducing incidence, transmission, and public health impact. Key strategies include:

TB Vaccination: BCG Vaccine: The Bacillus Calmette-Guérin (BCG) vaccine is the only licensed vaccine for TB and is primarily administered to infants in high-burden countries to prevent severe forms of TB, such as TB meningitis and disseminated TB in children. Early Detection and Treatment: Active Case Finding: Actively searching for individuals with TB symptoms and conducting diagnostic tests for prompt identification. Diagnostic Testing: Utilizing rapid and accurate diagnostic tests, such as molecular-based assays (e.g., GeneXpert), chest X-rays, and sputum microscopy. Early initiation of appropriate anti-TB treatment is critical to prevent disease progression and transmission. [43] [44]

Infection Control Measures

Isolating infectious TB patients in well-ventilated or negative-pressure rooms is vital to prevent airborne transmission. Promoting respiratory hygiene practices, such as covering the mouth and nose when coughing or sneezing, helps reduce transmission. Identifying and screening close contacts of TB patients to detect latent TB infection or active disease early is essential. High-risk populations should also be screened. [45] [46].

Preventive Therapy

Providing preventive therapy, such as isoniazid, to individuals with LTBI to lower their risk of developing active TB. Offering preventive therapy to high-risk groups, including individuals living with HIV/AIDS, children under five, and household contacts of TB patients. [47]

Community Engagement and Education

Educating the public about TB transmission, symptoms, prevention, and treatment helps reduce stigma and encourages early healthcare-seeking behavior. Engaging communities in TB prevention and control efforts through health workers, peer educators, and mobilization activities. [48]

Health System Strengthening

Ensuring access to affordable and high-quality TB diagnostic, treatment, and care services for all individuals. Training healthcare workers in TB diagnosis, treatment, infection control, and patient-centered care.

Addressing Social Determinants of Tuberculosis

Tackling socioeconomic factors, such as poverty and inadequate healthcare access, that contribute to TB transmission and poor outcomes. Improving nutritional status and housing conditions can reduce the risk of TB infection and disease progression.

Global Collaboration and Funding

Collaboration between countries and organizations to support global TB control efforts Integrating. TB prevention into broader health and development agendas, such as universal health coverage. By implementing these strategies, countries can work towards reducing TB's burden and achieving targets set by global elimination initiatives.

CURRENT RESEARCH AND FUTURE DIRECTIONS

The emergence of Multidrug-Resistant (MDR) and Extensively Drug-Resistant (XDR) Tuberculosis (TB) represents a formidable challenge to global health, particularly in high-burden countries like Pakistan. The multifaceted nature of these challenges, which includes increased treatment costs, the need for specialized healthcare personnel, inadequate diagnostic infrastructure, and the socio-economic ramifications for affected individuals and families, underscores the urgency for comprehensive and coordinated public health responses. Effective management of drug-resistant TB necessitates a robust combination of enhanced diagnostic capabilities, effective treatment regimens, patient education, and community engagement. Furthermore, addressing the socio-economic factors contributing to TB transmission and treatment outcomes is crucial for reducing the burden of this disease. Sustained commitment to research, innovation, and international collaboration will be vital for achieving the ambitious goal of eliminating TB as a public health threat by 2030.

According to this research we suggest some future directions aspect of better diagnosis and preventation of this disease spread.

Invest in the development and implementation of rapid, accurate diagnostic technologies, including point-of-care tests, to facilitate early detection of both drug-susceptible and drug-resistant TB. Expanding the use of molecular and imaging technologies can improve diagnostic accuracy and reduce delays in treatment initiation. Focus on research to establish optimized treatment regimens for MDR and XDR TB that reduce treatment duration and pill burden while ensuring efficacy. This includes the exploration of host-directed therapies and new drug combinations. Build and enhance healthcare infrastructure to support TB diagnosis and treatment, particularly in rural and underserved areas. This includes training healthcare providers in advanced diagnostic techniques and patient management. Implement comprehensive public health strategies that incorporate community engagement, public awareness campaigns, and patient support systems. Efforts should also focus on reducing stigma associated with TB to encourage early diagnosis and treatment adherence. Prioritize research into novel vaccines and therapies to address the growing challenge of drug-resistant TB. Investing in the development of effective vaccines can play a crucial role in preventing the disease, especially in high-burden settings. Develop policies that address the socio-economic determinants of health impacting TB transmission and treatment adherence. This includes improving access to healthcare services, financial support for affected individuals, and initiatives aimed at poverty alleviation. Foster multi-sectoral collaborations between government, NGOs, and international organizations to strengthen TB control programs and resource allocation. Engaging diverse stakeholders can enhance the reach and impact of TB control efforts. Advocate for increased political commitment and funding for TB control initiatives at national and global levels.

Sustained political will is essential for implementing effective policies and ensuring the allocation of necessary resources to combat MDR and XDR TB.

1. Saeed M, Rasool MH, Rasheed F, Saqalein M, Nisar MA, Imran AA, Tariq S, Amir A, Ikram A, Khurshid M. Extended-spectrum beta-lactamases producing extensively drug-resistant Salmonella Typhi in Punjab, Pakistan. The Journal of Infection in Developing Countries. 2020 Feb 29;14(02):169-76.
2. Zahid I, Sarwar A, Hussain A, Sohail M, Amin A. Antibiotyping and genotyping of extensively drug‐resistant (XDR) Salmonella sp. isolated from clinical samples of Lahore, Pakistan. Journal of applied microbiology. 2022 Jan 1;132(1):633-41.
3. Zakir M, Khan M, Umar MI, Murtaza G, Ashraf M, Shamim S. Emerging trends of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Salmonella Typhi in a tertiary care Hospital of Lahore, Pakistan. Microorganisms. 2021 Nov 30;9(12):2484.
4. Abubakar M, Ahmad N, Ghafoor A, Latif A, Ahmad I, Atif M, Saleem F, Khan S, Khan A, Khan AH. Treatment outcomes of extensively drug-resistant tuberculosis in Pakistan: a countrywide retrospective record review. Frontiers in Pharmacology. 2021 Mar 31;12:640555.
5. Abubakar M, Ahmad N, Ghafoor A, Latif A, Ahmad I, Atif M, Saleem F, Khan S, Khan A, Khan AH. Treatment outcomes of extensively drug-resistant tuberculosis in Pakistan: a countrywide retrospective record review. Frontiers in Pharmacology. 2021 Mar 31;12:640555.
6. Akram J, Khan AS, Khan HA, Gilani SA, Akram SJ, Ahmad FJ, Mehboob R. Extensively drug‐resistant (XDR) typhoid: evolution, prevention, and its management. BioMed Research International. 2020;2020(1):6432580.
7. Ejaz H, Younas S, Qamar MU, Junaid K, Abdalla AE, Abosalif KO, Alameen AA, Elamir MY, Ahmad N, Hamam SS, Salem EH. Molecular epidemiology of extensively drug-resistant mcr encoded colistin-resistant bacterial strains co-expressing multifarious β-lactamases. Antibiotics. 2021 Apr 20;10(4):467.
8. Ghafoor A, Mehraj J, Afridi ND, Rafiq Y, Wendl-Richter HU, Hasan R. Multidrug resistant Mycobacterium tuberculosis amongst Category I & II failures and Category II relapse patients from Pakistan. International journal of mycobacteriology. 2012 Sep 1;1(3):118-23.
9. Sabir N, Hussain W, Ahmed A, Zaman G, Mirza IA, Ikram A. Burden of multi-drug resistant, extensively-drug resistant and pan-drug resistant superbugs isolated from various indoor microbiological specimens at tertiary care centers Rawalpindi. Pakistan Armed Forces Medical Journal. 2020 Feb 28;70(1):79-85.
10. Sabir N, Hussain W, Ahmed A, Zaman G, Mirza IA, Ikram A. Burden of multi-drug resistant, extensively-drug resistant and pan-drug resistant superbugs isolated from various indoor microbiological specimens at tertiary care centers Rawalpindi. Pakistan Armed Forces Medical Journal. 2020 Feb 28;70(1):79-85.
11. Napier G, Khan AS, Jabbar A, Khan MT, Ali S, Qasim M, Mohammad N, Hasan R, Hasan Z, Campino S, Ahmad S. Characterisation of drug-resistant Mycobacterium tuberculosis mutations and transmission in Pakistan. Scientific reports. 2022 May 11;12(1):7703.
12. Tahseen S, Qadeer E, Khanzada FM, Rizvi AH, Dean A, Van Deun A, Zignol M. Use of Xpert® MTB/RIF assay in the first national anti-tuberculosis drug resistance survey in Pakistan. The International Journal of Tuberculosis and Lung Disease. 2016 Apr 1;20(4):448-55.
13. Saeed DK, Shakoor S, Razzak SA, Hasan Z, Sabzwari SF, Azizullah Z, Kanji A, Nasir A, Shafiq S, Ghanchi NK, Hasan R. Variants associated with Bedaquiline (BDQ) resistance identified in Rv0678 and efflux pump genes in Mycobacterium tuberculosis isolates from BDQ naïve TB patients in Pakistan. BMC microbiology. 2022 Feb 25;22(1):62.
14. Saleem S, Bokhari H. Resistance profile of genetically distinct clinical Pseudomonas aeruginosa isolates from public hospitals in central Pakistan. Journal of infection and public health. 2020 Apr 1;13(4):598-605.
15. Ayaz A, Hasan Z, Jafri S, Inayat R, Mangi R, Channa AA, Malik FR, Ali A, Rafiq Y, Hasan R. Characterizing Mycobacterium tuberculosis isolates from Karachi, Pakistan: drug resistance and genotypes. International Journal of Infectious Diseases. 2012 Apr 1;16(4):e303-9.
16. Noor R, Akhter S, Rahman F, Munshi SK, Kamal SM, Feroz F. Frequency of extensively drug-resistant tuberculosis (XDR-TB) among re-treatment cases in NIDCH, Dhaka, Bangladesh. Journal of Infection and Chemotherapy. 2013 Jan 1;19(2):243-8.
17. Nicol MP, Wilkinson RJ. The clinical consequences of strain diversity in Mycobacterium tuberculosis. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2008 Oct 1;102(10):955-65.
18. Keane J, Remold HG, Kornfeld H. Virulent Mycobacterium tuberculosis strains evade apoptosis of infected alveolar macrophages. The Journal of Immunology. 2000 Feb 15;164(4):2016-20.
19. Ohno H, Koga H, Kohno S, Tashiro T, Hara K. Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan. Antimicrobial agents and chemotherapy. 1996 Apr;40(4):1053-6.
20. Van Deun A, Barrera L, Bastian I, Fattorini L, Hoffmann H, Kam KM, Rigouts L, Rusch-Gerdes S, Wright A. Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. Journal of clinical microbiology. 2009 Nov;47(11):3501-6.
21. Pang Y, Zhou Y, Zhao B, Liu G, Jiang G, Xia H, Song Y, Shang Y, Wang S, Zhao YL. Spoligotyping and drug resistance analysis of Mycobacterium tuberculosis strains from national survey in China. PloS one. 2012 Mar 7;7(3):e32976.
22. Bouwman AS, Kennedy SL, Müller R, Stephens RH, Holst M, Caffell AC, Roberts CA, Brown TA. Genotype of a historic strain of Mycobacterium tuberculosis. Proceedings of the National Academy of Sciences. 2012 Nov 6;109(45):18511-6.
23. Zhang M, Gong J, Lin Y, Barnes PF. Growth of virulent and avirulent Mycobacterium tuberculosis strains in human macrophages. Infection and immunity. 1998 Feb 1;66(2):794-9.
24. Richardson M, Carroll NM, Engelke E, Van Der Spuy GD, Salker F, Munch Z, Gie RP, Warren RM, Beyers N, Van Helden PD. Multiple Mycobacterium tuberculosis strains in early cultures from patients in a high-incidence community setting. Journal of Clinical Microbiology. 2002 Aug;40(8):2750-4.
25. Cohen T, van Helden PD, Wilson D, Colijn C, McLaughlin MM, Abubakar I, Warren RM. Mixed-strain Mycobacterium tuberculosis infections and the implications for tuberculosis treatment and control. Clinical microbiology reviews. 2012 Oct;25(4):708-19.
26. Manabe YC, Dannenberg Jr AM, Tyagi SK, Hatem CL, Yoder M, Woolwine SC, Zook BC, Pitt ML, Bishai WR. Different strains of Mycobacterium tuberculosis cause various spectrums of disease in the rabbit model of tuberculosis. Infection and immunity. 2003 Oct;71(10):6004-11.
27. Nicol MP, Wilkinson RJ. The clinical consequences of strain diversity in Mycobacterium tuberculosis. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2008 Oct 1;102(10):955-65.
28. Pang Y, Zhou Y, Zhao B, Liu G, Jiang G, Xia H, Song Y, Shang Y, Wang S, Zhao YL. Spoligotyping and drug resistance analysis of Mycobacterium tuberculosis strains from national survey in China. PloS one. 2012 Mar 7;7(3):e32976.
29. Ribeiro SC, Gomes LL, Amaral EP, Andrade MR, Almeida FM, Rezende AL, Lanes VR, Carvalho EC, Suffys PN, Mokrousov I, Lasunskaia EB. Mycobacterium tuberculosis strains of the modern sublineage of the Beijing family are more likely to display increased virulence than strains of the ancient sublineage. Journal of clinical microbiology. 2014 Jul;52(7):2615-24.
30. Sharaf Eldin GS, Fadl-Elmula I, Ali MS, Ali AB, Salih AL, Mallard K, Bottomley C, McNerney R. Tuberculosis in Sudan: a study of Mycobacterium tuberculosis strain genotype and susceptibility to anti-tuberculosis drugs. BMC infectious diseases. 2011 Dec;11:1-8.
31. Kanduma E, McHugh TD, Gillespie SH. Molecular methods for Mycobacterium tuberculosis strain typing: a users guide. Journal of applied microbiology. 2003 May 1;94(5):781-91.
32. Betts JC, Dodson P, Quan S, Lewis AP, Thomas PJ, Duncan K, McAdam RA. Comparison of the proteome of Mycobacterium tuberculosis strain H37Rv with clinical isolate CDC 1551. Microbiology. 2000 Dec;146(12):3205-16.
33. Braden CR, Morlock GP, Woodley CL, Johnson KR, Colombel AC, Cave MD, Yang Z, Valway SE, Onorato IM, Crawford JT. Simultaneous infection with multiple strains of Mycobacterium tuberculosis. Clinical Infectious Diseases. 2001 Sep 15;33(6):e42-7.
34. Cannas A, Mazzarelli A, Di Caro A, Delogu G, Girardi E. Molecular typing of Mycobacterium tuberculosis strains: a fundamental tool for tuberculosis control and elimination. Infectious Disease Reports. 2016 Jun 24;8(2):6567.
35. Cohen T, van Helden PD, Wilson D, Colijn C, McLaughlin MM, Abubakar I, Warren RM. Mixed-strain Mycobacterium tuberculosis infections and the implications for tuberculosis treatment and control. Clinical microbiology reviews. 2012 Oct;25(4):708-19.
36. Cubillos-Ruiz A, Morales J, Zambrano MM. Analysis of the genetic variation in Mycobacterium tuberculosis strains by multiple genome alignments. BMC research notes. 2008 Dec;1:1-0.
37. Desjardins CA, Cohen KA, Munsamy V, Abeel T, Maharaj K, Walker BJ, Shea TP, Almeida DV, Manson AL, Salazar A, Padayatchi N. Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance. Nature genetics. 2016 May;48(5):544-51.
38. Feuerriegel S, Oberhauser B, George AG, Dafae F, Richter E, Rüsch-Gerdes S, Niemann S. Sequence analysis for detection of first-line drug resistance in Mycobacterium tuberculosis strains from a high-incidence setting. BMC microbiology. 2012 Dec;12:1-0.
39. Cannas A, Mazzarelli A, Di Caro A, Delogu G, Girardi E. Molecular typing of Mycobacterium tuberculosis strains: a fundamental tool for tuberculosis control and elimination. Infectious Disease Reports. 2016 Jun 24;8(2):6567.
40. Chevrel-Dellagi D, Abderrahman AM, Haltiti RA, Koubaji HI, Gicquel B, Dellagi K. Large-scale DNA fingerprinting of Mycobacterium tuberculosis strains as a tool for epidemiological studies of tuberculosis. Journal of clinical microbiology. 1993 Sep;31(9):2446-50.
41. Cubillos-Ruiz A, Morales J, Zambrano MM. Analysis of the genetic variation in Mycobacterium tuberculosis strains by multiple genome alignments. BMC research notes. 2008 Dec;1:1-0.
42. Daffé M, Lacave C, LANÉELLE MA, Lanéelle G. Structure of the major triglycosyl phenol‐phthiocerol of Mycobacterium tuberculosis (strain Canetti). European Journal of Biochemistry. 1987 Aug;167(1):155-60.
43. Gu S, Chen J, Dobos KM, Bradbury EM, Belisle JT, Chen X. Comprehensive Proteomic Profiling of the Membrane Constituents of a Mycobacterium tuberculosis Strain* S. Molecular & Cellular Proteomics. 2003 Dec 1;2(12):1284-96.
44. Gutacker MM, Mathema B, Soini H, Shashkina E, Kreiswirth BN, Graviss EA, Musser JM. Single-nucleotide polymorphism–based population genetic analysis of Mycobacterium tuberculosis strains from 4 geographic sites. The Journal of infectious diseases. 2006 Jan 1;193(1):121-8.
45. Hanekom M, Mata D, van Pittius NG, van Helden PD, Warren RM, Hernandez-Pando R. Mycobacterium tuberculosis strains with the Beijing genotype demonstrate variability in virulence associated with transmission. Tuberculosis. 2010 Sep 1;90(5):319-25.
46. Hillemann DRüsch-Gerdes S, Richter E.2007.Evaluation of the GenoType MTBDRplus Assay for Rifampin and Isoniazid Susceptibility Testing of Mycobacterium tuberculosis Strains and Clinical Specimens. J Clin Microbiol45: https://doi.org/10.1128/jcm.00521-07
47. Hirsh AE, Tsolaki AG, DeRiemer K, Feldman MW, Small PM. Stable association between strains of Mycobacterium tuberculosis and their human host populations. Proceedings of the National Academy of Sciences. 2004 Apr 6;101(14):4871-6.
48. Hillemann D, Rüsch-Gerdes S, Richter E. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. Journal of clinical microbiology. 2007 Aug;45(8):2635-40.
49. Kamerbeek J, Schouls LE, Kolk A, Van Agterveld M, Van Soolingen D, Kuijper S, Bunschoten A, Molhuizen H, Shaw R, Goyal M, van Embden J. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. Journal of clinical microbiology. 1997 Apr;35(4):907-14.
50. Baber, M., Islam, K., Ullah, A., & Ullah, W. (2024). Libraries in the Age of Intelligent Information: AI-Driven Solutions . International Journal of Applied and Scientific Research, 2(1), 153–176. https://doi.org/10.59890/ijasr.v2i1.1295
51. Kamerbeek J, Schouls LE, Kolk A, Van Agterveld M, Van Soolingen D, Kuijper S, Bunschoten A, Molhuizen H, Shaw R, Goyal M, van Embden J. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. Journal of clinical microbiology. 1997 Apr;35(4):907-14.